Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL513250 | 1.00 | L3MBTL1 (0.56) | L3MBTL1PKMKMT2ARECQLTBXAS1 | |
| SCHEMBL8437521 | 1.00 | L3MBTL1 (0.56) | L3MBTL1PKMKMT2ARECQLTBXAS1 | |
| Hydrochloric Acid SCHEMBL8439653 | 0.98 | TBXAS1 (0.55) | L3MBTL1PKMKMT2ARECQLTBXAS1 | |
| Hydrochloric Acid SCHEMBL8439652 | 0.98 | TBXAS1 (0.55) | L3MBTL1PKMKMT2ARECQLTBXAS1 | |
| SCHEMBL8803619 | 0.86 | RECQL (0.60) | L3MBTL1PKMKMT2ARECQLHPGD | |
| SCHEMBL6421087 | 0.85 | ALDH1A1 (0.57) | L3MBTL1PKMKMT2ARECQLKDM4E | |
| SCHEMBL8843480 | 0.85 | L3MBTL1 (0.53) | L3MBTL1PKMKMT2ARECQLTBXAS1 | |
| Hydrochloric Acid SCHEMBL8843446 | 0.84 | TBXAS1 (0.52) | L3MBTL1PKMKMT2ARECQLTBXAS1 | |
| SCHEMBL8843081 | 0.82 | PDCD1 (0.52) | L3MBTL1PKMKMT2ARECQLTBXAS1 | |
| SCHEMBL17623604 | 0.82 | TBXAS1 (0.55) | L3MBTL1TBXAS1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007054348-A1 | NOVEL MEDICAMENTS | Ernst-Moritz-Arndt-Universität Greifswald (DE) | 2007-05-18 | — | — | WO | claimed |
| US-5916906-A | TREATMENT OF NEURODEGENERATIVE DISORDERS, VIRAL INFECTIONS, AUTOIMMUNE DISEASES | SHASKAN EDWARD G (US) | 1999-06-29 | — | — | US | claimed |
| EP-0814812-A1 | COMPOSITIONS COMPRISING NICOTYNYLALANINE AND AN INHIBITOR OF GLYCINE CONJUGATION OR VITAMIN B6 | Shaskan, Edward G. (US) | 1998-01-07 | — | — | EP | claimed |
| WO-1996028167-A1 | COMPOSITIONS COMPRISING NICOTYNYLALANINE AND AN INHIBITOR OF GLYCINE CONJUGATION OR VITAMIN B6 | SHASKAN EDWARD G (US) | 1996-09-19 | — | — | WO | claimed |
| EP-0532545-A1 | NICOTINYLALANINE AS A THERAPEUTIC AGENT ACTING ON THE CENTRAL NERVOUS SYSTEM | FIDIA S.p.A. (IT) | 1993-03-24 | — | — | EP | claimed |
| WO-1991017750-A1 | NICOTINYLALANINE AS A THERAPEUTIC AGENT ACTING ON THE CENTRAL NERVOUS SYSTEM | FIDIA S.P.A. (IT) | 1991-11-28 | — | — | WO | claimed |
| CN-118139636-A | Delivery of promoted concentrated antibody formulations using hyaluronidase | 武田药品工业株式会社 | 2024-06-04 | — | — | CN | disclosed |
| EP-3070475-B1 | IN VITRO DIAGNOSTIC, PROGNOSIS OF CONTRAST INDUCED NEPHROPATHY | KELLNER KARL HEINZ (DE) | 2020-02-19 | — | — | EP | disclosed |
| WO-2016193499-A1 | IMMUNOMODULATORY ANTIBODY OR IMMUNOTHERAPEUTIC, AGENT WHICH INCREASES AND/OR MIMICKS KYNURENINE, AND OPTIONAL COMBINATION THEREOF | IMMUSMOL SAS (FR) | 2016-12-08 | — | — | WO | disclosed |
| EP-3070475-A2 | IN VITRO DIAGNOSTIC, PROGNOSIS OF CONTRAST INDUCED NEPHROPATHY | Kellner, Karl-Heinz (DE) | 2016-09-21 | — | — | EP | disclosed |
| US-9290518-B2 | Water soluble metal-organic frameworks (MOFs) | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-03-22 | — | — | US | disclosed |
| US-20120029015-A1 | Novel medical use of kynurenic acid, its precursors and derivatives | MARCINIAK ANDRZEJ (PL) | 2012-02-02 | — | — | US | disclosed |
| WO-2010110689-A1 | A NOVEL MEDICAL USE OF KYNURENIC ACID, ITS PRECURSORS AND DERIVATIVES | MARCINIAK ANDRZEJ (PL) | 2010-09-30 | — | — | WO | disclosed |
| WO-1996028167-A1 | COMPOSITIONS COMPRISING NICOTYNYLALANINE AND AN INHIBITOR OF GLYCINE CONJUGATION OR VITAMIN B6 | SHASKAN EDWARD G (US) | 1996-09-19 | — | — | WO | disclosed |
| US-5495044-A | Inhibitors of kynureninase | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1996-02-27 | — | — | US | disclosed |
| WO-1995011878-A1 | INHIBITORS OF KYNURENINASE | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1995-05-04 | — | — | WO | disclosed |
| EP-0532545-A1 | NICOTINYLALANINE AS A THERAPEUTIC AGENT ACTING ON THE CENTRAL NERVOUS SYSTEM | FIDIA S.p.A. (IT) | 1993-03-24 | — | — | EP | disclosed |
| EP-0532545-A1 | NICOTINYLALANINE AS A THERAPEUTIC AGENT ACTING ON THE CENTRAL NERVOUS SYSTEM | FIDIA S.p.A. (IT) | 1993-03-24 | — | — | EP | disclosed |
| WO-1991017750-A1 | NICOTINYLALANINE AS A THERAPEUTIC AGENT ACTING ON THE CENTRAL NERVOUS SYSTEM | FIDIA S.P.A. (IT) | 1991-11-28 | — | — | WO | disclosed |
| WO-1991017750-A1 | NICOTINYLALANINE AS A THERAPEUTIC AGENT ACTING ON THE CENTRAL NERVOUS SYSTEM | FIDIA S.P.A. (IT) | 1991-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029015-A1 | Novel medical use of kynurenic acid, its precursors and derivatives | FFAR3, FFAR2, HCAR2 | L3MBTL1 4010/4885PKM 2452/4885KMT2A 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.